Alkermes sees future for Vivitrol; Abraxane makes progress in urothelial cancer;

> Waltham, MA-based Alkermes’s ($ALKS) once-monthly formulation of naltrexone (Vivitrol) has fallen short of some people’s expectations in the market for treating alcohol addiction, yet the company sees a future for the treatment to help people kick their opioid habits. Story

> Researchers say that nanoparticle albumin-bound paclitaxel (Abraxane) is making progress in Phase II study as a second-line treatment for metastatic urothelial cancer. Story

> Pacira Pharmaceuticals ($PCRX) released new safety data from a Phase III trial of its extended-release form of bupivacaine, Exparel, showing that the treatment was well tolerated in patients after surgeries to remove bunions. The firm filed papers with the FDA for approval of the experimental product for treating pain after surgeries in September 2010; the agency is expected to complete its review of the drug by July 28. Pacira release

> Business Insights, a market research firm, forecasts that the market for drug-delivery devices is poised to grow to $24.5 billion by 2015. Release

> Micell Technologies of Durham, NC, has enrolled the first person a clinical trial to study its "MiStent" drug-eluting coronary stent for patients with angina pectoris and ischemia. The 270-patient study is being done in order to gain CE Mark approval of the firm's experimental stent. Release

> TransPharma Medical of Lod, Israel, has wrapped up a Phase Ib trial of its treatment for type 2 diabetes mellitus, ViaDor-GLP1, which involves the use of a handheld device that delivers a drug via micro-channels into the outer layer of the skin. Story